Samsung Biologics Co Ltd

Overview

Samsung Biologics Co Ltd (Samsung Biologics) is a biologics development and manufacturing company. The company’s business activities include process development and formulation, contract manufacturing, and project management. Samsung Biologics cell culture development process includes upstream, downstream and analytical technology. Samsung Biologics’ provides manufacturing and quality assurance for the clinical and commercial products. In addition, the company also offers infrastructure for partnership with other organizations to develop, refine, and distribute the bio-pharmaceutical products. It owns manufacturing facilities for cell culture development, purification, quality control, MSAT laboratory. Samsung Biologics is headquartered in Incheon, South Korea.
Key Stats
Address
300, Songdo bio-daero, Yeonsu-gu, Yeonsu-gu, INCHEON, South Korea
Headquarters

South Korea

Contact

82 32 4553114

No of Employees

2,587

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

207940 [KOSE]

Revenue (2020)

$988 m

64% (2020 vs 2019)
Net Income (2020)

$204 m

17.1% (2020 vs 2019)
Net Profit Margin

21 %

-28.5% (2020 vs 2019)
Market Cap *

$53,239 m

EPS *

$3.1

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Samsung Biologics Co LtdCelltrion Healthcare Co LtdEnsol Biosciences Inc
Key Information
Headquarters South Korea South Korea South Korea
Headquarter City INCHEON INCHEON DAEJEON
Headquarter State/Province - - -
No. of Employees 2,587 - -
Entity Type Public Public Public

Products & Services

Samsung Biologics manufactures bio-healthcare products. The company's key services include the following:

Services
  • Contract Manufacturing:
  • Analytical Services
  • API Biologics (Protein and Peptide)
  • Etiam Rutrum Elit
  • Etiam Rutrum Elit
  • Etiam Rutrum Elit
  • Etiam Rutrum Elit
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 New Products/Services In May, the company announced to add mRNA vaccine drug substance manufacturing capability to expand…
2021 Contracts/Agreements In April, the company and TG Therapeutics announced the expansion of a contract manufacturing agreement…
2020 Contracts/Agreements In September, the company entered into a service agreement with Panolos Bioscience to develop PB101,…
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Samsung Bioepis Co Ltd

Address

107, Cheomdan-daero, Yeonsu, Incheon
South Korea

Telephone

82 32 4556114

Website

www.samsungbioepis.com

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
20 Jul 2021 Kineta Enters Manufacturing Agreement with Samsung Biologics for KVA12.1 Contract Service Agreement Kineta Inc Samsung Biologics Co Ltd
04 Jun 2021 Elevation Oncology Enters API Manufacturing Agreement with Samsung Biologics for Seribantumab Contract Service Agreement Elevation Oncology Inc Samsung Biologics Co Ltd
02 Jun 2021 KAHR medical Enters Manufacturing Agreement with Samsung Biologics for DSP502 Contract Service Agreement KAHR medical Ltd Samsung Biologics Co Ltd
23 May 2021 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
14 Apr 2021 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
02 Nov 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit